NeoGenomics, Inc. has launched PTEN IHC CDx, an FDA-approved immunohistochemistry companion diagnostic for identifying patients with PTEN-deficient prostate adenocarcinoma who may be eligible for AstraZeneca’s Truqap, or capivasertib. The test is available as a standalone order and through NEO PanTracer Pro for prostate cancer across the diagnostics company’s national laboratory network.
The launch converts a recent drug and device approval into a service that oncologists and pathologists can order through an established cancer-testing provider. The underlying VENTANA PTEN SP218 RxDx Assay was developed by Roche Diagnostics and approved by the United States Food and Drug Administration alongside capivasertib for PTEN-deficient metastatic androgen pathway modulation-naïve or sensitive prostate cancer, a disease category previously described as metastatic hormone-sensitive prostate cancer.
That distinction is commercially important. NeoGenomics is not introducing a new assay that has independently secured regulatory clearance. It is using its pathology infrastructure, ordering relationships and national laboratory reach to make the approved Roche Diagnostics test more accessible, particularly to community oncology practices that may not perform the companion diagnostic internally.
Why does the NeoGenomics PTEN companion diagnostic matter after the Truqap approval?
A targeted cancer medicine cannot reach its intended population consistently unless clinicians have practical access to the test specified in its regulatory indication. The approval of capivasertib created the therapeutic option, but the commercial and clinical value of that approval depends on whether patients are tested at the appropriate stage of disease and whether results are returned quickly enough to inform treatment planning.
The FDA approved capivasertib in combination with abiraterone and prednisone on June 12, 2026 for adults with metastatic androgen pathway modulation-naïve or sensitive prostate cancer whose tumours are PTEN-deficient. The regulator simultaneously approved the VENTANA PTEN SP218 RxDx Assay as the companion diagnostic required to identify the relevant biomarker-defined population.
NeoGenomics is positioning itself between those two parts of the treatment pathway. It can receive tumour tissue, perform the approved immunohistochemistry procedure, provide a pathologist-interpreted result and, where ordered through NEO PanTracer Pro, combine the PTEN assessment with broader molecular and ancillary testing.
This may reduce fragmentation for clinicians who would otherwise need to coordinate different laboratories for immunohistochemistry, comprehensive genomic profiling and other prostate cancer tests. The practical advantage is less about introducing another biomarker and more about placing a newly actionable biomarker into a familiar ordering and reporting system.
The unresolved issue is testing behaviour. A companion diagnostic can be nationally available without becoming routinely ordered. NeoGenomics will still need to educate oncologists, urologists and pathologists about the new indication, the appropriate disease setting and the difference between PTEN protein loss measured by immunohistochemistry and PTEN alterations that may appear on genomic reports.
How does PTEN IHC testing determine whether a prostate cancer patient may be eligible for Truqap?
PTEN is a tumour suppressor involved in controlling signalling through the PI3K and AKT pathway. Loss of PTEN activity can remove an important restraint on cancer-cell growth and is associated with a more aggressive form of prostate cancer.
The NeoGenomics service assesses PTEN protein expression in viable tumour cells using the SP218 antibody clone. Under the approved scoring method, a tumour is classified as showing PTEN loss when at least 90% of viable malignant cells lack specific cytoplasmic staining. The assay is performed on the Ventana BenchMark ULTRA platform using formalin-fixed, paraffin-embedded prostate cancer tissue.
Immunohistochemistry offers several operational advantages. It is already widely used in anatomic pathology, it evaluates protein expression directly within tumour tissue and it can provide visual context that helps pathologists distinguish tumour cells from surrounding non-malignant structures. NeoGenomics has said that standalone results may be delivered in as few as one to two days, although actual turnaround will depend on specimen receipt, tissue quality and whether additional work is required.
The scoring threshold also demands consistency. Small tissue samples, prior treatment, fixation conditions, tumour heterogeneity and limited viable cancer content can complicate biomarker interpretation. The preferred submission is a formalin-fixed, paraffin-embedded tissue block, and laboratories need sufficient tumour material to perform the stain while preserving tissue for other clinically relevant tests.
Centralised testing may improve standardisation because trained pathologists can apply one validated assay and interpretation framework across a large specimen volume. It may also introduce transport time, tissue-handling requirements and dependence on an external laboratory. Hospitals and oncology practices will need to weigh those factors against the benefit of avoiding local assay validation and maintaining access to a test tied directly to the drug label.
What did CAPItello-281 show, and how strong is the clinical case behind PTEN testing?
The companion diagnostic’s relevance rests on the CAPItello-281 Phase 3 trial, which enrolled 1,012 adults with newly diagnosed PTEN-deficient metastatic prostate cancer. Participants received capivasertib with abiraterone and androgen-deprivation therapy or placebo with abiraterone and androgen-deprivation therapy.
The combination reduced the risk of radiographic disease progression or death by 19%. Median radiographic progression-free survival reached 33.2 months with capivasertib, compared with 25.7 months in the control group, representing a 7.5-month difference. Overall survival results were not mature at the primary analysis.
Those results provide a clear basis for biomarker testing, but they do not remove questions about the treatment’s place in clinical practice. A 19% relative reduction in progression risk is meaningful in an aggressive molecular subgroup, although it is more measured than the dramatic effects sometimes associated with highly selective targeted therapies.
Treatment selection will also depend on tolerability. The capivasertib regimen carries risks including hyperglycaemia, diarrhoea and cutaneous reactions. In CAPItello-281, Grade 3 or higher adverse events occurred in 67% of patients receiving the capivasertib combination, with severe rash and hyperglycaemia among the more frequent events.
Testing therefore identifies potential eligibility rather than guaranteeing that every PTEN-deficient patient will receive the medicine. Clinicians must still consider disease burden, existing conditions, metabolic risk, previous treatment, patient fitness and alternative intensification strategies.
The commercial performance of PTEN IHC CDx will consequently be tied to confidence in the treatment package, not only confidence in the assay. If capivasertib is incorporated into treatment guidelines and adopted broadly in the eligible population, testing demand should follow. If physicians reserve the combination for a narrower group because of toxicity, cost or uncertainty around mature survival results, companion diagnostic volumes could develop more gradually.
Can NEO PanTracer Pro make PTEN testing easier for community oncology practices?
NeoGenomics is offering PTEN IHC CDx both independently and as part of NEO PanTracer Pro, a prostate cancer testing workflow that combines comprehensive genomic profiling with cancer-directed immunohistochemistry and ancillary testing.
The bundled approach addresses a recurring problem in precision oncology. Clinicians increasingly need multiple types of information, yet no single technology answers every treatment question. Genomic profiling can detect mutations, copy-number changes, rearrangements and other molecular features. Immunohistochemistry evaluates protein expression within tissue. Additional pathology tests may confirm tumour origin, classification or other therapeutically relevant characteristics.
Integrating these modalities into one coordinated order may simplify sample management and reporting. It may also reduce the risk that a practice orders broad sequencing but overlooks a treatment-linked protein biomarker that requires an approved immunohistochemistry method.
The benefit will depend on how clearly the final report communicates actionable findings. Broader panels can generate large quantities of information, and not every alteration has an approved therapy attached to it. The PTEN result needs to be prominent, linked to the correct disease stage and distinguished from other findings that may be prognostic, investigational or relevant only after disease progression.
There is also a cost and reimbursement question. A standalone PTEN assay may be appropriate when other molecular work has already been completed, while a broader PanTracer order may be more useful for newly diagnosed metastatic patients who require a comprehensive assessment. Payers may evaluate those pathways differently, and practices will need clarity on coverage, patient financial exposure and documentation requirements.
NeoGenomics will have to demonstrate that the integrated model improves ordering efficiency without encouraging unnecessary testing. Adoption is likely to be strongest where the company can show predictable turnaround times, adequate reimbursement support and reports that fit naturally into existing clinical workflows.
Is PTEN IHC CDx likely to become a meaningful growth driver for NeoGenomics?
For NeoGenomics, the immediate revenue contribution from one companion diagnostic is unlikely to transform the business. The strategic value lies in extending its prostate cancer portfolio, strengthening NEO PanTracer Pro and demonstrating that the company can rapidly operationalise biomarker tests connected to newly approved therapies.
NeoGenomics reported first-quarter 2026 revenue of $187 million, an 11% increase from the previous year. Adjusted EBITDA increased 27% to $9 million, while its net loss narrowed to $17 million. The diagnostics provider revised its full-year revenue guidance to between $797 million and $803 million, suggesting that investors are already evaluating the business through a broader combination of test-volume growth, pricing, portfolio expansion and improving operating leverage.
PTEN IHC CDx supports that portfolio strategy because it can generate testing revenue directly while making the broader PanTracer offering more relevant. It also strengthens NeoGenomics’ value to pharmaceutical partners seeking laboratories capable of supporting companion diagnostic deployment beyond major academic cancer centres.
The financial effect will depend on the size of the tested population. Approximately 35,000 patients in the United States are diagnosed annually with metastatic androgen pathway modulation-naïve or sensitive prostate cancer, and an estimated one in four has PTEN-deficient disease. That implies a potentially eligible population of about 8,750 patients annually, although actual testing volumes may differ because some patients will already have tissue results, receive testing elsewhere or not enter the treatment pathway targeted by the approval.
The opportunity is therefore commercially useful but bounded. NeoGenomics will be competing for specimens with hospital laboratories, academic centres and other reference laboratories capable of offering the approved assay. Its national reach and community oncology relationships are advantages, but they do not guarantee market share.
What does the latest NeoGenomics stock performance reveal about investor sentiment?
NeoGenomics shares closed at $14.11 on July 10, 2026, falling approximately 4.2% during the session. The stock declined about 6.9% from its July 6 close but remained roughly 24% above its June 10 level, placing it closer to the upper end of its 52-week range of $4.72 to $15.57.
That pattern points to improving medium-term sentiment accompanied by near-term volatility. The PTEN diagnostic launch is an incremental commercial catalyst rather than an event likely to determine the company’s valuation by itself. Investors are more likely to assess it as evidence that NeoGenomics is executing its product-expansion strategy and building a wider menu of treatment-linked tests.
The next substantial test of sentiment will be the company’s second-quarter financial report, scheduled for July 28, 2026. Investors will be watching clinical testing growth, average revenue per test, margins, operating cash use and progress across PanTracer, minimal residual disease testing and the company’s newer oncology products.
PTEN IHC CDx adds another reason for oncologists to use the NeoGenomics network, but the market will want evidence that portfolio additions are translating into order growth and improved profitability. The launch strengthens the company’s position in precision oncology. Its significance will ultimately be measured by how often physicians test eligible patients, how quickly results influence treatment decisions and whether NeoGenomics captures a meaningful share of the emerging PTEN-directed prostate cancer testing market.
